Legend Biotech has managed to remove GenScript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuver ...
SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...
LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech ...
GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...
In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...
GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the ...
Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...
PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...
At a time when biotech is increasingly central to global health, and climate resilience, GenScript's ESG Report demonstrates how the company is embedding sustainability, governance, and societal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results